The clinical efficacy of glitinides is similar to that of the sulfonylureas. In short-term, placebo-controlled trials, repaglinide monotherapy reduced HbA1C levels from 8.5% at baseline to 7.8% after only 12 weeks. In individuals with T2DM not previously treated with other oral hypoglycemic agents, repaglinide resulted in a 30% decrease in HbA1C, from 6.9% to 4.8%, with fasting and postprandial blood glucose levels decreased by 70 and 112mgdL_ 1, respectively. Repaglinide59 and nateglinide60 as combination therapy with metformin are more effective than either agent alone. Glitinides are taken before every meal but are not taken if a meal is skipped.
Was this article helpful?